ZW25 Effective in HER2-Positive Cancers
A novel anti-HER2 therapy, ZW25, may be effective and well tolerated in patients with a variety of HER2-positive cancers. In a phase I trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had an objective response rate of 41% and mild side effects.
Gespeichert in:
| Veröffentlicht in: | Cancer discovery 2019-01, Vol.9 (1), p.8-8 |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | A novel anti-HER2 therapy, ZW25, may be effective and well tolerated in patients with a variety of HER2-positive cancers. In a phase I trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had an objective response rate of 41% and mild side effects. |
|---|---|
| ISSN: | 2159-8274 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-NB2018-162 |